|
t3
<br />14.
<br />l5
<br />16.
<br />l7
<br />l8
<br />l9
<br />20.
<br />2l
<br />resolved prior to that date. A list of all Litigating subdivisions known to the partiesis included in Exhibit F hereto.
<br />"Net settlement Amount" means the amount paid by Janssen into the SettrementFund under subsection v.c' For the avoidan"" oraou[i,?. N", settlement Amountdoes not include amounts paid for state outside ano tnsiaetounsel Fees and costspursuant to subsection IX.A.
<br />'I;fr:r:!f"{ing Subdivision,meansa Subdivision rhat is nor a Litigating
<br />"Non-Party covered conduct craim- means a Craimagainst any Non-RereasedEntity involving, arising out of; or rela-ted to covered C?"J""t (or conduct thatwould be covered conduct if engaged inby an.r"ur.o EnJtyr
<br />"Non-Party settrement" means a settlement by any Releasor that settles any Non-Party covered conduct craim and incruder u..r.u.. oiun|'Non-n"reased Entity.
<br />"Non-Released Entity" means an entity that is not a Rereased Entity.
<br />"opioid Remediation" means care, treatment, and other programs and expenditures(including reimbursement for past su.h ptog.urs or expenditures except where thisAgreement restricts rhe use orfunds sotity i9 n t"1. oil;ilii.rediation) designedto (1) address rhe misuse and.abuse of opioid qr;";:Aj;;" or mitigare opioiduse or related disorders, or (3) mitigate other utt.g.J .ir.Jrr'"rrrre opioid abusecrisis, including on those injured uJu."*utt of the opioid abuse crisis. Exhibit Jprovides a non-exhaustive list of expenJitures that {u"riry "ri"i"g paid for opioidRemediation' Qual i $ring expenditu;r ;"y include r.uronuut. related adm inistrativeexpenses.
<br />"Participating subdivision" means a Subdivision that meets the requirements forbecoming a participating subdivirionlno". Section VIL
<br />"Parties" means Janssen and the State of washington (each, a,,parry,,).
<br />"Product" means any chemical substance, whether used for medicinal or non_medicinal purposes' and whethe. nutu.ui, ,ynthetic, or semi-synthetic, or anyfinished pharmaceutical product tua. r.L. or with such subJtance, that is an opioidor opiate, as weil as any product containing any such substance. It arso incrudes: r)th e fo I I owin g when ur"d'i n .om ur nution
<br />-1I1
<br />"n
<br />i
<br />"r
<br />a9 ;;6;;, b enzo diazepine,carisoprodol, zolpidem,.or gabapentin; and 2) a combin",ii"
<br />",
<br />,,cocktair,, of anystimulant or other chemicar-su.b;*;;p;;cribed, sord, bought, or dispensed to beused together that includes op.ioids o. Jfiut.r. For the avoid"ance of doubt, ,,product,,
<br />does not include benzodiazepin., .Jrffidor, zorpidem, or gabapentin when notused in combination with opioid. o, opiit.r. ..product,o incruies but is not rimited toany substance consisting ofor containing buprenorphine, codeine, fentanyr,hydrocodone, hydromo.phon", r.t;.il;;;, methadone, morphine, naroxone,
<br />a
<br />-t
|